Toleranzia develops drugs that utilize the immune system’s own intrinsic power to treat autoimmune orphan diseases. The drugs that target the cause of the disease can cure or greatly alleviate the disease and not only reduce the symptoms which currently available treatments do. The company’s drug candidate, TOL2, is being developed for the autoimmune nerve and muscle disease myastenia gravis.
Toleranzia’s vision is to provide new medicines to treat and cure patients with autoimmune diseases.
The company’s internal focus is on preclinical and early clinical research and development, in parallel with business development to find suitable partner for commercialization. Continued clinical development and commercialization will take place in partnership with leading pharmaceutical companies.
Main business-related goals
Toleranzia initially focuses on drug development for the disease myasthenia gravis and the drug candidate TOL2. In parallel, the company also conducts academic and commercial collaborations in autoimmune diseases and continuously evaluates new cutting-edge technologies, as a way to maximize the value of the projects.
The company’s three-year goal is to have successfully completed a clinical phase I/IIa study, to have entered into a TOL2 outlicensing agreement, and to have identified and initiated preclinical development of a new drug candidate within a second autoimmune disease.